Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.40 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3702267 | 0.74 | LRRK2 (0.42) | BRD4PDE10A | |
| SCHEMBL3707400 | 0.69 | BTK (0.34) | — | |
| SCHEMBL19484607 | 0.67 | CREBBP (0.65) | BRD4ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL30756343 | 0.67 | KEAP1 (0.42) | ADORA2A | |
| SCHEMBL25430654 | 0.67 | BRD4 (0.42) | BRD4ADORA2AADORA1DYRK1ACREBBP | |
| SCHEMBL15784006 | 0.66 | ATR (0.47) | BRD4ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL25258561 | 0.66 | BRD4 (0.49) | BRD4ADORA2AADORA1ADORA2BDYRK1A | |
| SCHEMBL3702232 | 0.65 | DYRK1A (0.50) | ADORA2BDYRK1A | |
| SCHEMBL30880494 | 0.65 | BRD4 (0.64) | BRD4ADORA2AADORA1ADORA2BCREBBP | |
| SCHEMBL31359456 | 0.65 | BRD4 (0.41) | BRD4ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012064269-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064269-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | APP, BACE1, PSEN1 | BRD4 3621/4885ADORA2A 1739/4885ADORA1 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.